Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517307 · ClinicalTrials.gov registry record · NA
Fatty Acid Oxidation Defects and Insulin Sensitivity
A NA study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT02517307 is a NA study that has completed, run by Oregon Health and Science University. The registered enrollment target is 41 participants.
The verdict
NCT02517307, a NA study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about what causes insulin resistance. It has been suggested that proper breakdown of fat into energy (oxidation) in the body is important to allow insulin to keep blood sugar in the normal range. The investigators want to know if having one of the fatty acid oxidation disorders could have an influence on insulin action. Fatty acid oxidation disorders are genetic disorders that inhibit one of the enzymes that converts fat into energy. The investigators will study both normal healthy people and people with a long-chain fatty acid oxidation disorder.
Interventions
- DRUG Intralipid/Heparin
- DRUG Glycerol/Saline
- DRUG Hyperinsulinemic euglycemic clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-02 |
| Est. Completion | 2021-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02517307
The ClinicalTrials.gov registry entry for NCT02517307 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Intralipid/Heparin is the first listed.
NCT02517307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02517307 about?
NCT02517307 is a clinical study titled "Fatty Acid Oxidation Defects and Insulin Sensitivity". The purpose of this study is to learn more about what causes insulin resistance. It has been suggested that proper breakdown of fat into energy (oxidation) in the body is important to allow insulin to keep blood sugar in the normal range. The investigators want to know if having one of the fatty aci...
What is the current status of trial NCT02517307?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2016-02. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02517307?
The interventions under investigation include: Intralipid/Heparin (DRUG), Glycerol/Saline (DRUG), Hyperinsulinemic euglycemic clamp (DRUG).
Who is sponsoring clinical trial NCT02517307?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.